Abstract:BackgroundAnterior gradient homolog 2 (AGR2) is a functional protein with critical roles in a diverse range of biological systems, including vertebrate tissue development, inflammatory tissue injury responses, and cancer progression. Clinical studies have shown that the AGR2 protein is overexpressed in a wide range of human cancers, including carcinomas of the esophagus, pancreas, breast, prostate, and lung, making the protein as a potential cancer biomarker. However, the general biochemical functions of AGR2 in human cells remain undefined, and the signaling mechanisms that drive AGR2 to inhibit p53 are still not clearly illustrated. Therefore, it is of great interest to develop molecular probes specifically recognizing AGR2 for its detection and for the elucidation of AGR2-associated molecular mechanism.Methodology/principal findingsThrough a bead-based and flow cytometry monitored SELEX technology, we have identified a group of DNA aptamers that can specifically bind to AGR2 with K(d) values in the nanomolar range after 14 rounds of selections. Aptamer C14B was chosen to further study, due to its high binding affinity and specificity. The optimized and shortened C14B1 has special G-rich characteristics, and the G-rich region of this binding motif was further characterized to reveal an intramolecular parallel G-quadruplex by CD spectroscopy and UV spectroscopy. Our experiments confirmed that the stability of the G-quadruplex structure was strongly dependent on the nature of the monovalent ions and the formation of G-quadruplex structure was also important for the binding capacity of C14B1 to the target. Furthermore, we have designed a kind of allosteric molecule beacon (aMB) probe for selective and sensitive detection of AGR2.Conclusion/significanceIn this work, we have developed new aptamer probes for specific recognition of the AGR2. Structural study have identified that the binding motif of aptamer is an intramolecular parallel G-quadruplex structure and its structure and binding affinity are strongly dependent on the nature of the monovalent ion. Furthermore, with our design of AGR2-aMB, AGR2 could be sensitively and selectively detected. This aptamer probe has great potential to serve as a useful tool for early diagnosis and prognosis of cancer and for fundamental research to elucidate the biochemical functions of AGR2.

A Non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer (Adv. Healthcare Mater. 20/2023)

A non‐G‐Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer

Data from Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

Functionalized Aptamer with an Antiparallel G-quadruplex: Structural Remodeling, Recognition Mechanism, and Diagnostic Applications Targeting CTGF.

Locked Nucleic Acid/dna Chimeric Aptamer Probe for Tumor Diagnosis with Improved Serum Stability and Extended Imaging Window in Vivo.

Identification, characterization and application of a G-quadruplex structured DNA aptamer against cancer biomarker protein anterior gradient homolog 2.

Biological functions and clinical significance of long noncoding RNAs in bladder cancer

Clinical applications of nucleic acid aptamers in cancer.

Nucleic Acid Aptamers: an Emerging Frontier in Cancer Therapy

Building a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy.

Synthetic Artificial "long Non-Coding RNAs" Targeting Oncogenic Micrornas and Transcriptional Factors Inhibit Malignant Phenotypes of Bladder Cancer Cells

Proteomic and Transcriptome Profiling of G-Quadruplex Aptamers Developed for Cell Internalization.

Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine

Technetium‐99m Radiolabeled Nucleolin-Targeted Aptamer for Glioma Tumor Imaging in Murine Models

Self-assembly of DNA nanostructure containing cell-specific aptamer as a precise drug delivery system for cancer therapy in non-small cell lung cancer

DNA-Based Nanomedicine with Targeting and Enhancement of Therapeutic Efficacy of Breast Cancer Cells

Supplementary Data from Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer

A Cell-Based Single-Stranded DNA Aptamer Specifically Targets Gastric Cancer

Palindrome-mediated DNA nanotubes with cell-specific aptamers to improve targeted antitumor effects and reduce toxicity on non-small cell lung cancer

Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA Aptamer